Blog
RSS FeedPosted by Michael Wonder on 20 Oct 2025
Ipsen’s Bylvay launches in Korea with national coverage for a rare childhood liver disease
20 October 2025 - Ipsen Korea has rolled out Bylvay (odevixibat) in Korea with national health insurance coverage, giving children ...
Posted by Michael Wonder on 02 Oct 2025
PHARMAC proposes changes to make it easier to access HIV medicines
1 October 2025 - New Zealanders living with, or at risk of, HIV could soon benefit from proposed changes to ...
Posted by Michael Wonder on 01 Oct 2025
New Zealand Pharmaceutical Schedule - 1 October 2025
1 October 2025 - The October 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Sep 2025
Schedule of Pharmaceutical Benefits - 1 October 2025
1 October 2025 - The October 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 29 Sep 2025
New life changing medicines listed on the PBS
28 September 2025 - From 1 October 2025, Australians affected by breast cancer and rare kidney disease will have access ...
Posted by Michael Wonder on 27 Sep 2025
Major breast cancer treatment cost slashed under new PBS listing
28 September 2025 - Thousands of women will pay significantly less for treatment after the Federal Government listed a leading ...
Posted by Michael Wonder on 26 Sep 2025
HIRA calls for insurance overhaul to ensure access to high cost orphan drugs
26 September 2025 - The Government has proposed that a new health insurance reimbursement system must be designed to ensure ...
Posted by Michael Wonder on 24 Sep 2025
PHARMAC proposes funding five medicines and more convenient treatment options to ease pressure on health services
24 September 2025 - New Zealanders living with multiple sclerosis, breast cancer, eye conditions, and lung cancer could benefit from ...
Posted by Michael Wonder on 24 Sep 2025
Push for taxpayers to fund weight loss drugs for 500,000 Australians
23 September 2025 - Danish pharmaceutical giant Novo Nordisk has asked the Federal Government to subsidise its blockbuster weight loss ...
Posted by Michael Wonder on 23 Sep 2025
GLP-1 drugs Ozempic and Mounjaro close to reimbursement in diabetes care
23 Septemner 2025 - With GLP-1 receptor agonists nearing reimbursement for diabetes treatment, the Government is preparing tighter oversight and ...
Posted by Michael Wonder on 17 Sep 2025
Besremi gains reimbursement as second-line therapy for polycythemia vera in Korea
27 August 2025 - PharmaEssentia Korea announced on Wednesday that Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera, will be ...
Posted by Michael Wonder on 16 Sep 2025
AbbVie's Vraylar (cariprazine) now publicly reimbursed in Alberta
15 September 2025 - AbbVie announced today that Alberta has listed Vraylar (cariprazine) on its Health Drug Formulary. ...
Posted by Michael Wonder on 11 Sep 2025
Doctor treating patients with neurofibromatosis calls for rectifying inconsistent reimbursement standards for Koselugo
26 August 2025 - Last Thursday, people gathered in front of HIRA in Seoul, holding signs that read, “Ignoring doctors' ...
Posted by Michael Wonder on 10 Sep 2025
Enhanced access to generalised myasthenia gravis treatments: UCB Canada secures pCPA agreements for Zilbrysq and Rystiggo
9 September 2025 - Important milestone brings eligible Canadians living with generalised myasthenia gravis one step closer to accessing innovative ...
Posted by Michael Wonder on 10 Sep 2025
Pfizer's Prevnar 20 selected for pneumococcal public immunisation program in British Columbia
9 September 2025 - Today, Pfizer Canada announced that its 20 valent pneumococcal conjugate vaccine, Prevnar 20, has been selected for ...